Literature DB >> 15599803

Nicotinic acetylcholine receptor system and neuropsychiatric disorders.

Abhay Singh1, Alexandra Potter, Paul Newhouse.   

Abstract

Investigations into the neurobiology, and biophysical and pharmacological properties of nicotinic receptors, also known as nicotinic acetylcholine receptors (nAChRs), have led to an improved understanding of their role in a variety of neuropsychiatric disorders. There is a growing body of evidence linking alterations in nicotinic receptor number and/or function to conditions such as schizophrenia, Alzheimer's disease, Parkinson's disease, anxiety disorders, mood disorders, and attention deficit-hyperactivity disorder. The implications of nicotine receptor modulation upon the clinical expression and progression of these disorders is currently under investigation, utilizing techniques that include psychopharmacological, cognitive, electrophysiological and neuroimaging analysis. This review attempts to outline evidence pertaining to the role of the nicotinic receptor system in various neuropsychiatric disorders in the context of understanding appropriate targets for therapeutic drug development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15599803

Source DB:  PubMed          Journal:  IDrugs        ISSN: 1369-7056


  18 in total

1.  Differential expression and function of nicotinic acetylcholine receptors in the urinary bladder epithelium of the rat.

Authors:  Jonathan M Beckel; Lori A Birder
Journal:  J Physiol       Date:  2012-01-16       Impact factor: 5.182

2.  Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity.

Authors:  Alexandra S Potter; David J Bucci; Paul A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  2011-10-04       Impact factor: 4.530

3.  Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention.

Authors:  Britta Hahn; Katelyn E Riegger; Greg I Elmer
Journal:  Psychopharmacology (Berl)       Date:  2016-02-15       Impact factor: 4.530

4.  Nicotine deprivation influences P300 markers of cognitive control.

Authors:  David E Evans; Nathan D Maxfield; Kate Janse Van Rensburg; Jason A Oliver; Kade G Jentink; David J Drobes
Journal:  Neuropsychopharmacology       Date:  2013-06-28       Impact factor: 7.853

Review 5.  Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date.

Authors:  Alexandra S Potter; Geoffrey Schaubhut; Megan Shipman
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

6.  Nicotine exposure during adolescence: cognitive performance and brain gene expression in adult heterozygous reeler mice.

Authors:  Emilia Romano; Federica De Angelis; Lisa Ulbrich; Antonella De Jaco; Andrea Fuso; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2013-12-13       Impact factor: 4.530

7.  Nicotine restores Wt-like levels of reelin and GAD67 gene expression in brain of heterozygous reeler mice.

Authors:  Emilia Romano; Andrea Fuso; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

Review 8.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 9.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

Review 10.  The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.

Authors:  Sharon R Grady; Outi Salminen; Duncan C Laverty; Paul Whiteaker; J Michael McIntosh; Allan C Collins; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.